TAE684 (NVP-TAE684)

TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.

Price Stock Quantity  
USD 160 In stock
USD 290 In stock
USD 770 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

TAE684 (NVP-TAE684) Chemical Structure

TAE684 (NVP-TAE684) Chemical Structure
Molecular Weight: 614.2

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

ALK Inhibitors with Unique Features

  • Non-specific ALK Inhibitor

    GSK1838705A IGF-1R, IC50=2.0 nM; IR, IC50=1.6 nM, ALK, IC50=0.5 nM.

  • Most Potent ALK Inhibitor

    Ceritinib (LDK378) ALK, IC50=0.2 nM.

  • FDA-approved ALK Inhibitor

    Crizotinib (PF-02341066) Approved by FDA for non-small cell lung carcinoma (NSCLC).

  • Newest ALK Inhibitor

    ASP3026 Novel and selective inhibitor for ALK with IC50 of 3.5 nM.

Product Information

  • Compare ALK Inhibitors
    Compare ALK Products
  • Research Area
  • TAE684 (NVP-TAE684) Mechanism

Product Description

Biological Activity

Description TAE684 (NVP-TAE684) is a potent and selective ALK inhibitor with IC50 of 3 nM in a cell-free assay, 100-fold more sensitive for ALK than InsR.
Targets ALK [1]
(Cell-free assay)
IC50 3 nM
In vitro TAE684 does not exhibit significant cross-reactivity against other kinases. TAE684 potently inhibits the proliferation of Ba/F3 NPM-ALK cells with IC50 of 3 nM, without affecting the survival of Ba/F3 cells even at 1 μM. TAE684 also inhibits proliferation of NPM-ALK-expressing human ALCL cell lines including Karpas-299 and SU-DHL-1 with IC50 of 2–5 nM. Molecular modeling reveals that L258 may be one of the major kinase-selectivity determinants for TAE684. TAE684 treatment results in a rapid and sustained inhibition of phosphorylation of NPM-ALK. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. [1] TAE684 markedly overcomes Crizotinib-resistance in H3122 CR cells, harboring the fusion oncogene EML4-ALK, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis.[2] Neurite outgrowth induced by expression of the mALK R1279Q mutant could be completely inhibited by TAE684 at 30 nM. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SCC-3NHPkW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIO3SnFKSzVyPUCuNFAxODZyMzFOwG0>NUDGSnpYW0GQR1XS
SF539NGnTN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7aV3NKSzVyPUCuNFAxPTZ2IN88US=>MYLTRW5ITVJ?
DELMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFficWJKSzVyPUCuNFAxQTJ5IN88US=>NVrURYhbW0GQR1XS
NB1NFTjSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnRSJNWUUN3ME2wMlAxOTZ{IN88US=>M3TlW3NCVkeHUh?=
SRM13tNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLyTWM2OD1yLkCwNlc4KM7:TR?=NGHxeVhUSU6JRWK=
KARPAS-299M37ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDKTWM2OD1yLkCyN|g1KM7:TR?=MmjQV2FPT0WU
MHH-CALL-2NGnxeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjpfmdbUUN3ME2wMlAzQTV{IN88US=>M4PTXHNCVkeHUh?=
SU-DHL-1NIjT[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[xWWt[UUN3ME2wMlA1QDZ3IN88US=>MlPmV2FPT0WU
A4-FukNFXyZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MljLTWM2OD1yLkC1OVY2KM7:TR?=NXrPW|Z6W0GQR1XS
EW-1NGHaUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HMbmlEPTB;MD6xNFI2PiEQvF2=NVfTVmZ[W0GQR1XS
NOS-1NEnP[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMUCyPVQh|ryPMUnTRW5ITVJ?
EW-16M13veWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEe2d4dKSzVyPUCuNVA2PjhizszNNHK5UopUSU6JRWK=
TE-11NEnUfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrhTWM2OD1yLkG2NFk3KM7:TR?=NWfrXXRsW0GQR1XS
SW982MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fuZWlEPTB;MD6xOlQ4QCEQvF2=NIPxfWlUSU6JRWK=
LAN-6MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DGbWlEPTB;MD6xO|Q1OyEQvF2=NGr1NopUSU6JRWK=
MZ1-PCMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHOxZWhKSzVyPUCuNVc5OzVizszNNW\Zb2MxW0GQR1XS
KS-1M{OwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrLTGdKSzVyPUCuNVk{PDNizszNMVLTRW5ITVJ?
PSN1Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\CZZZVUUN3ME2wMlE6PjNzIN88US=>NUTuSXNVW0GQR1XS
LC-2-adMkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULRWFdlUUN3ME2wMlE6Pjl{IN88US=>NUiyZ|d6W0GQR1XS
COLO-320-HSRMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfRTWM2OD1yLkG5O|c3KM7:TR?=MWnTRW5ITVJ?
OPM-2M1Tjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH2Z5BlUUN3ME2wMlIzPjZ7IN88US=>NXnMcXZiW0GQR1XS
SK-NEP-1M3jGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\JWGlEPTB;MD6yN|UzPCEQvF2=NFzHRm5USU6JRWK=
ALL-POMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGLyUJpKSzVyPUCuNlQ2OjRizszNMV\TRW5ITVJ?
CMKNHHiTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHrTWM2OD1yLkK1OVMh|ryPNH\mfnpUSU6JRWK=
NCI-H1648Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDvZohKSzVyPUCuNlc5PTVizszNMW\TRW5ITVJ?
SIG-M5M4G4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PRUWlEPTB;MD6yPVE2QSEQvF2=MX3TRW5ITVJ?
TGBC24TKBNIO4boxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTISVdUUUN3ME2wMlMxOjF6IN88US=>NHLxOnJUSU6JRWK=
DOHH-2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTBwM{GyNFQh|ryPMYHTRW5ITVJ?
NB69MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwM{G3PFch|ryPMX\TRW5ITVJ?
MFH-inoMmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwM{K1NlMh|ryPNETFOI1USU6JRWK=
KP-N-RT-BM-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfJN|FKSzVyPUCuN|MyOjNizszNNH70b|dUSU6JRWK=
MONO-MAC-6MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1[yNGlEPTB;MD6zN|I6OSEQvF2=M1r5Z3NCVkeHUh?=
ATN-1Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIroeHNKSzVyPUCuN|M{ODNizszNMoDzV2FPT0WU
NTERA-S-cl-D1NUD1WVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\MRmlEPTB;MD6zN|M6PiEQvF2=MlfIV2FPT0WU
L-540NFLLd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTBwM{[5PFgh|ryPNXvhNG02W0GQR1XS
GB-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjyfIlXUUN3ME2wMlM5QDZ5IN88US=>M2fBfHNCVkeHUh?=
MV-4-11NWTFd3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\NWHJKSzVyPUCuN|k1PDZizszNMnPmV2FPT0WU
KG-1NYHS[Ww5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTBwM{m1OlEh|ryPMV7TRW5ITVJ?
OVCAR-4NHvZR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELNWXNKSzVyPUCuOFA2PjlizszNNX;RS|ZsW0GQR1XS
NEC8NXHtVmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zkbGlEPTB;MD60NVI6OiEQvF2=MmnyV2FPT0WU
SK-MM-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwNEG2NFkh|ryPMVrTRW5ITVJ?
TE-8MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfoV3pKSzVyPUCuOFI5QCEQvF2=MVHTRW5ITVJ?
697MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\mXlE2UUN3ME2wMlQ{OjF3IN88US=>NGHo[GFUSU6JRWK=
NB14M{GzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Sze2lEPTB;MD60N|gzPiEQvF2=MXTTRW5ITVJ?
GDM-1Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HjTGlEPTB;MD60O|EyPiEQvF2=NXXaXGZDW0GQR1XS
HUTU-80NUTEUotUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXmyOVZXUUN3ME2wMlQ4Ozd3IN88US=>NEDxWIhUSU6JRWK=
HL-60MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTBwNEixOFIh|ryPNGfCdJdUSU6JRWK=
OCI-AML2M4rVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFW5UYtKSzVyPUCuOFg{OjhizszNMn\0V2FPT0WU
ML-2MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTQcZpmUUN3ME2wMlQ6ODNzIN88US=>MV;TRW5ITVJ?
ES4MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nDeWlEPTB;MD60PVExQSEQvF2=MkXRV2FPT0WU
NCI-H747MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYP1ZYViUUN3ME2wMlQ6QDlizszNMUTTRW5ITVJ?
RL95-2MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXKT2dGUUN3ME2wMlUxOTF{IN88US=>Mlr1V2FPT0WU
TE-15MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrhTFdTUUN3ME2wMlUyOTJ2IN88US=>MoqwV2FPT0WU
TE-12M{nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnDdI9KSzVyPUCuOVM{PDlizszNM3\CTXNCVkeHUh?=
LB1047-RCCNHnUdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHuOnVPUUN3ME2wMlU1PTR7IN88US=>NX7jfWRxW0GQR1XS
LB831-BLCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDiOHFKSzVyPUCuOVUxOjNizszNMn;FV2FPT0WU
NCI-H1355M2fwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWq2fJdqUUN3ME2wMlU2OTh2IN88US=>NX6xPJljW0GQR1XS
CTV-1M4POSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\VRmlEPTB;MD61OVYzPCEQvF2=M4KxZnNCVkeHUh?=
RXF393NXj5[IdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjNTWM2OD1yLkW1O|k1KM7:TR?=MXvTRW5ITVJ?
SW872NXL6WoZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\2NXZYUUN3ME2wMlU3PzJ2IN88US=>M2TVc3NCVkeHUh?=
MPP-89NW\LNYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXuTWM2OD1yLkW3PFg1KM7:TR?=NF[zUmhUSU6JRWK=
RPMI-8226NIXNXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVj4THlFUUN3ME2wMlY{PTJ4IN88US=>MV\TRW5ITVJ?
LS-1034NXPjUXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPmTWM2OD1yLk[zOVgh|ryPMXXTRW5ITVJ?
SJSA-1NFntSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4W0NGlEPTB;MD62N|czPSEQvF2=MVrTRW5ITVJ?
HOP-62M2XnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3ryZmlEPTB;MD62OVA{OyEQvF2=NHjjNFVUSU6JRWK=
KGNM{\3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1S5fGlEPTB;MD62OlE3QCEQvF2=MorHV2FPT0WU
D-336MGNV[0cVVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTmTWM2OD1yLk[2NVY6KM7:TR?=M3K1ZnNCVkeHUh?=
LS-411NM{[zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTBwNke0OlIh|ryPMVHTRW5ITVJ?
TE-1MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXDTWM2OD1yLk[5NFc1KM7:TR?=MoLKV2FPT0WU
LB996-RCCMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFT6O4hKSzVyPUCuOlk{QDlizszNM{D3bnNCVkeHUh?=
TE-10NUHnUXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYexU45zUUN3ME2wMlcyPDl4IN88US=>NXTYWGRwW0GQR1XS
NCI-SNU-16NHvQTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P6[GlEPTB;MD63NlY3PCEQvF2=NXXWTm5XW0GQR1XS
ES8Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwN{S5O|Uh|ryPMnf5V2FPT0WU
COLO-800NUe3NXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfMeGxKSzVyPUCuO|Y3QTVizszNNV7GVW46W0GQR1XS
ES6M3vjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLHTWM2OD1yLke3OVU6KM7:TR?=NF\GS3hUSU6JRWK=
L-363M3nj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYCzeWtzUUN3ME2wMlgzOzd3IN88US=>NVWzWYNZW0GQR1XS
NMC-G1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M362fWlEPTB;MD64N|I{OyEQvF2=NYnS[5Q6W0GQR1XS
LU-134-AM{TlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTBwOEO5NVIh|ryPMVPTRW5ITVJ?
SF268MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTBwOESwOFIh|ryPMWrTRW5ITVJ?
KARPAS-45M1\wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVW0R4x[UUN3ME2wMlg1OjZ|IN88US=>NFu4R5FUSU6JRWK=
TGWMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPWTWM2OD1yLki1PFY{KM7:TR?=MnfwV2FPT0WU
CHP-126NWrHZnp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELr[XZKSzVyPUCuPFU6PTdizszNNX3K[FBUW0GQR1XS
MOLT-16M{GzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fZSmlEPTB;MD64O|U5QSEQvF2=NHLqfVBUSU6JRWK=
LB771-HNCM2nwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:2WmlEPTB;MD64PVc2PyEQvF2=NXjjU5JSW0GQR1XS
NALM-6MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1H3PGlEPTB;MD65NFc{QSEQvF2=M3TJXnNCVkeHUh?=
GCIYMmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmr5TWM2OD1yLkm1OVI3KM7:TR?=M3vFNXNCVkeHUh?=
IST-MES1M3nhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUTGTIdYUUN3ME2wMlk5QDJ2IN88US=>NXn6bnE2W0GQR1XS
LB2241-RCCM3fIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTBwOUi4OEDPxE1?NH3OPJpUSU6JRWK=
BL-70MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\PTWM2OD1yLkm5OVM2KM7:TR?=MVHTRW5ITVJ?
NB17NUPXNI9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYe3SWxwUUN3ME2xMlAxPjN7IN88US=>NHTVPZpUSU6JRWK=
LXF-289NXjZ[2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i5O2lEPTB;MT6wN|A4PiEQvF2=MnnsV2FPT0WU
TK10NEW3UIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX[xUFd1UUN3ME2xMlA2ODZ|IN88US=>NGHESYtUSU6JRWK=
K5NUHTWpdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTFwME[yO|Qh|ryPMlfMV2FPT0WU
NCI-H716NInBZ3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2T1cmlEPTB;MT6wO|I2QSEQvF2=NV\EfIZ7W0GQR1XS
HCE-TMnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknnTWM2OD1zLkC4PFE6KM7:TR?=NIjYSFRUSU6JRWK=
GI-1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP6WnpKSzVyPUGuNFk4QThizszNMYPTRW5ITVJ?
KARPAS-422M2LrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInwc|ZKSzVyPUGuNVAxOjJizszNM3zMbXNCVkeHUh?=
TE-9MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkfWTWM2OD1zLkGxN|I5KM7:TR?=NIrX[oJUSU6JRWK=
SF126M3yzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVT2elNKUUN3ME2xMlEyPTZ6IN88US=>MV7TRW5ITVJ?
BB30-HNCMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXLWFdKSzVyPUGuNVMyOTJizszNM3nHRXNCVkeHUh?=
NCI-H1304M{i0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlKyTWM2OD1zLkGzN|M5KM7:TR?=M3PaSXNCVkeHUh?=
HELM2DlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrTZ2NKSzVyPUGuNVQ5QTVizszNMkTYV2FPT0WU
HAL-01M1y2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTFwMUWyPFMh|ryPNIfKT4RUSU6JRWK=
SK-LMS-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTFwMUW5O|Qh|ryPMV\TRW5ITVJ?
SW954MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnaVpNNUUN3ME2xMlE6PTZ5IN88US=>M{jWOnNCVkeHUh?=
D-283MEDNUOyUJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NED3PHJKSzVyPUGuNlI{PzlizszNNGe1colUSU6JRWK=
NCI-H1882M4\ab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTFwMkO4PUDPxE1?MXTTRW5ITVJ?
GI-ME-NM1G3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn0TppKSzVyPUGuNlUzODhizszNNFHEdHdUSU6JRWK=
SK-PN-DWNFyzZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33yNGlEPTB;MT6yOlM1QCEQvF2=MYLTRW5ITVJ?
C2BBe1NYm2emxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlywTWM2OD1zLkK5NVE4KM7:TR?=MUDTRW5ITVJ?
A704NUG4bolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUm3c5lmUUN3ME2xMlMzPjh7IN88US=>NVK4NoFKW0GQR1XS
KALS-1NH7S[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwM{SwPEDPxE1?NY\oSFJZW0GQR1XS
ETK-1NWj3[FR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTFwM{S0PFkh|ryPNUn6TIZKW0GQR1XS
LB647-SCLCMl:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTFwM{S5PFYh|ryPMkC5V2FPT0WU
OCUB-MNEft[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LkdGlEPTB;MT6zOlE1OyEQvF2=NYLPSZE{W0GQR1XS
NCI-H720NVi1cGxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLkTWM2OD1zLkO2N|c5KM7:TR?=MVHTRW5ITVJ?
NB13M2rXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4e1cWlEPTB;MT6zO|I6OyEQvF2=NHjWTIdUSU6JRWK=
GR-STNW[yNI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{S2UWlEPTB;MT6zPFc2PyEQvF2=MorrV2FPT0WU
DU-4475MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jZU2lEPTB;MT60OVg2OyEQvF2=M{PKOnNCVkeHUh?=
HCC2157MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfLU2JyUUN3ME2xMlQ3PjV7IN88US=>NW\BfYxTW0GQR1XS
RKOMmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\PTWM2OD1zLkS5PVIzKM7:TR?=NI\vNW9USU6JRWK=
LS-123NYHP[2psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLie5ZKSzVyPUGuOVE2QTRizszNM4Gzd3NCVkeHUh?=
NCI-H69NF:xNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWGzfZhyUUN3ME2xMlU2QDFzIN88US=>MlziV2FPT0WU
SW962MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nNNGlEPTB;MT61OlE{KM7:TR?=NHrIVWhUSU6JRWK=
PF-382MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXlXYFKSzVyPUGuOVY6PiEQvF2=NWjkNXVzW0GQR1XS
A101DMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4OyUGlEPTB;MT61O|EyOyEQvF2=MYTTRW5ITVJ?
NB10NFvlXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjZTWM2OD1zLkW3N|kzKM7:TR?=MYTTRW5ITVJ?
NB5NWnLXHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moe3TWM2OD1zLkW4OFc3KM7:TR?=MoDwV2FPT0WU
HCE-4MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmLOTWM2OD1zLk[wPFUh|ryPMnLZV2FPT0WU
HT-144M2GyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fIU2lEPTB;MT62N|E6KM7:TR?=MoLJV2FPT0WU
NCI-H524NX;hfFZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;Jb4FKSzVyPUGuOlQ{ODdizszNMX7TRW5ITVJ?
NKM-1MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFKwSXdKSzVyPUGuOlg3PiEQvF2=NWX2XJFpW0GQR1XS
KURAMOCHIMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDZVlBqUUN3ME2xMlY6PTd|IN88US=>MV7TRW5ITVJ?
NCI-H187M2[xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37BemlEPTB;MT63NFA{PiEQvF2=NIjuNZFUSU6JRWK=
U-266NVmxfZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fyUGlEPTB;MT63N|g1OiEQvF2=NX3Ve3ZWW0GQR1XS
BL-41M4nrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYS5eo9SUUN3ME2xMlc3Ojd{IN88US=>MnrJV2FPT0WU
SK-N-DZNWS0d|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrSSG1KSzVyPUGuO|g{ODlizszNMmHwV2FPT0WU
DaudiNIrkUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWK4XnhKUUN3ME2xMlc5QTZ5IN88US=>Mk\MV2FPT0WU
CPC-NNXnSRpl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;J[GlEPTB;MT64OVA6PiEQvF2=MmLpV2FPT0WU
EM-2NFLSSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTFwOEWxJO69VQ>?NHzNOHJUSU6JRWK=
HCC1187NYXYb4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXMOWxKSzVyPUGuPFYzPDFizszNMYTTRW5ITVJ?
LP-1Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXlTWM2OD1zLki3NVQ{KM7:TR?=NFv1ZXVUSU6JRWK=
CAS-1NUfidW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTFwOUiyPVkh|ryPM4rXdnNCVkeHUh?=
NB7NGDndXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17JdWlEPTB;Mj6wNFU2PSEQvF2=NXOwRWVXW0GQR1XS
VA-ES-BJNWTFSFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTJwMEG1NVMh|ryPMX3TRW5ITVJ?
SNU-C2BNXfWS2Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTJwMEOzOVEh|ryPM2XqT3NCVkeHUh?=
LOXIMVIM1THW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJwME[3PFYh|ryPNGHycldUSU6JRWK=
NCI-H1581MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vrb2lEPTB;Mj6xNVU2QSEQvF2=M{XleXNCVkeHUh?=
IST-SL2NWG1XXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HoWmlEPTB;Mj6xNlQ1PSEQvF2=NGTuR|hUSU6JRWK=
NOMO-1M{Pidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfCTWM2OD1{LkG3Olg{KM7:TR?=MlL4V2FPT0WU
TE-6MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHhZWNKSzVyPUKuNVkxPSEQvF2=MUHTRW5ITVJ?
NCI-H526MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrBXpdyUUN3ME2yMlE6OTRzIN88US=>MUjTRW5ITVJ?
MSTO-211HMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTJwMkCwOFEh|ryPNUPkcYpZW0GQR1XS
LS-513NGXabW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\YTWM2OD1{LkKyNlY6KM7:TR?=MnraV2FPT0WU
NCI-SNU-1Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTWXWV{UUN3ME2yMlM{OjV4IN88US=>M2[1RXNCVkeHUh?=
BB65-RCCNEW2S2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHRRZhWUUN3ME2yMlM4PDl|IN88US=>MY\TRW5ITVJ?
GT3TKBNF:4bHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInMZ4tKSzVyPUKuN|k6PzJizszNNYLvN|BKW0GQR1XS
OS-RC-2NIL1NGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJwNEKzOFEh|ryPM1O5S3NCVkeHUh?=
NCI-H2126M2Ll[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2C2bmlEPTB;Mj60N|Y4PCEQvF2=M{n3UHNCVkeHUh?=
SK-UT-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXRTWM2OD1{LkS3OFY4KM7:TR?=MmH0V2FPT0WU
DMS-114NXq3c5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4i4VGlEPTB;Mj62NVUzPCEQvF2=NVjOd|lYW0GQR1XS
ONS-76NW\PSI97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jNcmlEPTB;Mj62N|Y1OSEQvF2=M3XQXHNCVkeHUh?=
8-MG-BAMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn33TWM2OD1{Lk[1OFE1KM7:TR?=Mo\uV2FPT0WU
BOKUNHzwXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3L4T2lEPTB;Mj63Nlc3PCEQvF2=NWDHbZJsW0GQR1XS
LAMA-84MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJwN{m5NVIh|ryPNIHtb3hUSU6JRWK=
ES1NYnRR|dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTJwOEG4NFQh|ryPM3W4WnNCVkeHUh?=
NCI-H1395MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LwZmlEPTB;Mj64NlAyOiEQvF2=NUP2NYxDW0GQR1XS
A388M1zhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnTTWM2OD1{Lkm2NVch|ryPMVXTRW5ITVJ?
NCCITNHm0dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTNwMEi4OlIh|ryPM{X5dHNCVkeHUh?=
HD-MY-ZNV;meJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKybolKSzVyPUOuNVMzODNizszNMXHTRW5ITVJ?
NCI-H510AMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL3d2JKSzVyPUOuNVg6PDNizszNMWrTRW5ITVJ?
NCI-N87M2LlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PEb2lEPTB;Mz6yNFAzKM7:TR?=NUXRO5lYW0GQR1XS
SCLC-21HNEewOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7XZYplUUN3ME2zMlI3QDV7IN88US=>NWnXSIExW0GQR1XS
SH-4MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfwZWNYUUN3ME2zMlI5Pzl5IN88US=>MY\TRW5ITVJ?
QIMR-WILMk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTNwM{K4OFkh|ryPNWLhU|BIW0GQR1XS
KM12MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXRTWM2OD1|LkOzOVQ1KM7:TR?=NXrVWIxMW0GQR1XS
ST486NV63ZmtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEO1emdKSzVyPUOuOVM5QDNizszNMVvTRW5ITVJ?
HC-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPvRoFKSzVyPUOuOlIxOjhizszNNWPrOpFPW0GQR1XS
BV-173M2rQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzKTWM2OD1|Lk[0NFg5KM7:TR?=M2jPNXNCVkeHUh?=
EW-24MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTNwNk[0N|Qh|ryPNEnH[2NUSU6JRWK=
LU-65M1ToRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTNwNki3NUDPxE1?NUn4NoJnW0GQR1XS
ECC4Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTNwN{e1OkDPxE1?M1HSdnNCVkeHUh?=
ARH-77NXO1bpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\pe5RKSzVyPUSuNVExPjdizszNMom5V2FPT0WU
BC-3MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHQN5dKSzVyPUSuNVMxPjhizszNNW\CV2xPW0GQR1XS
SNB75MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2raOGlEPTB;ND6yOlE6KM7:TR?=M3;HUnNCVkeHUh?=
MEG-01NUTMW2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXEeWVKUUN3ME20MlI4PDF7IN88US=>MYPTRW5ITVJ?
NCI-H1417M{ToPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnj[2lKSzVyPUSuNlg1PDNizszNM362W3NCVkeHUh?=
MDA-MB-134-VINUDmeYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXidppKSzVyPUSuN|A3ODFizszNM1W0T3NCVkeHUh?=
BeckerNXPkfJBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;hTWM2OD12LkS3N|M3KM7:TR?=NUXvdW57W0GQR1XS
DMS-153NETSWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLBTWM2OD12Lk[2OFc2KM7:TR?=MV;TRW5ITVJ?
TGBC1TKBM{PnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnyeVRKUUN3ME20MlY5PTF3IN88US=>MlizV2FPT0WU
EW-3M1PQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULqcpFEUUN3ME20Mlc3OjR6IN88US=>M{ezdXNCVkeHUh?=
KE-37NXjGeGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvYTWM2OD12Lki2NVk3KM7:TR?=MnTLV2FPT0WU
NCI-H23Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\VTWM2OD12Lki3NlI4KM7:TR?=MmnlV2FPT0WU
MC116MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHtdIRKSzVyPUSuPVQyOjZizszNMoKwV2FPT0WU
NH-12MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTRwOU[0N|kh|ryPNVrTXFBZW0GQR1XS
CTB-1M1:yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfGN5p3UUN3ME20Mlk4PzJzIN88US=>NF70bm1USU6JRWK=
KM-H2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTVwMEWzNlMh|ryPMYTTRW5ITVJ?
MOLT-4MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTUTWM2OD13LkGxPFMh|ryPNVnjfmhwW0GQR1XS
NCI-H2141Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGD3T2tKSzVyPUWuNVQzPjhizszNMYTTRW5ITVJ?
EB-3MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f3Z2lEPTB;NT6xO|UxPCEQvF2=NH3SRZVUSU6JRWK=
NCI-H1522MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXORnZUUUN3ME21MlI3OzJ{IN88US=>MojJV2FPT0WU
MRK-nu-1NHP5dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4L2TGlEPTB;NT60N|Y{OyEQvF2=NH;xPJlUSU6JRWK=
no-11NVz0T25pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTVwNEewPFch|ryPMWTTRW5ITVJ?
CESSNFL1WIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfZWGI4UUN3ME21MlU5ODN2IN88US=>Mnq2V2FPT0WU
KMOE-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTVwNUi2OVkh|ryPMonTV2FPT0WU
REHMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLETWM2OD14LkK1OlE5KM7:TR?=MUfTRW5ITVJ?
KU812MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;6OGlEPTB;Nj60Nlc6OSEQvF2=M3XOd3NCVkeHUh?=
SK-N-FIM4X5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jmbWlEPTB;Nj62NFY4PCEQvF2=MlHGV2FPT0WU
MMAC-SFNX7rUlNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTdwME[0PVIh|ryPM17TdHNCVkeHUh?=
RCC10RGBM4PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXm4b3hMUUN3ME23MlIzQTd5IN88US=>M1ThdnNCVkeHUh?=
NCI-H322MMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XUcGlEPTB;Nz6zN|M{PSEQvF2=NE[4eWtUSU6JRWK=
NB6MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTdwNUS4PVkh|ryPNIrROFNUSU6JRWK=
MN-60MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXpSZBZUUN3ME23MlY6OjF3IN88US=>NUDrU|l6W0GQR1XS
NCI-H1092NHzJS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTlTWM2OD16LkCxO|M1KM7:TR?=NYjYVIQxW0GQR1XS
EKVXMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPzd4pzUUN3ME24MlQ4ODZ4IN88US=>MW\TRW5ITVJ?
D-263MGMmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRThwNUWzPVYh|ryPMUDTRW5ITVJ?
NCI-H209NFnKOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWToWYw5UUN3ME24MlY1ODB4IN88US=>M4rxcXNCVkeHUh?=
IST-SL1MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInMWJBKSzVyPUiuPFk5QTJizszNM4S1SHNCVkeHUh?=
ACNMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkP0TWM2OD17LkG5NVU4KM7:TR?=NIXFdG5USU6JRWK=
MHH-PREB-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nYeGlEPTB;OT6yNVIyQSEQvF2=M2jEUXNCVkeHUh?=
EW-11M{D0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4fZdGlEPTB;OT62OVM6PiEQvF2=NIPwOZpUSU6JRWK=
KASUMI-1MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTlwN{i3O{DPxE1?MY\TRW5ITVJ?
KINGS-1MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLOfGhKSzVyPUGwMlI{PDdizszNM3v0WHNCVkeHUh?=
EVSA-TMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPs[XFKSzVyPUGwMlMyQTJizszNMVjTRW5ITVJ?
DSH1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTFyLkO5O|Ih|ryPMYjTRW5ITVJ?
COLO-824NFHEfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTFyLki2Olkh|ryPMV7TRW5ITVJ?
K052NIHwOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLMWpFKSzVyPUGwMlk{OjJizszNM3r1d3NCVkeHUh?=
SK-MEL-2NWXmWmlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2L0XWlEPTB;MUCuPVk{QSEQvF2=MYnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo After 4 weeks of treatment with TAE684 at 3 and 10 mg/kg, there is a significant delay in lymphoma development and 100- to 1,000-fold reduction in luminescence signal, without any signs of compound- or disease-related toxicity in Karpas-299 lymphoma model. TAE684 treatment also induces disease regression in established Karpas-299 lymphomas and down-regulates CD30 expression. [1] TAE684 also shows impressive antitumor activity against H3122 CR xenograft tumors. [2] Furthermore, treatment with TAE684 improves the rough eye phenotype of both ALK mutants, especially that seen with ALKR1275Q, whereas Crizotinib has little effect on either phenotype. [3]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro Enzyme Assays. All in vitro enzyme assays are done at Upstate Biotechnology with the exception of InsR and IGF-1R. To determine the IC50 of TAE684 against InsR and IGF-1R a homogeneous time-resolved fluorescence assay is performed. ATP (10 mM) and 20 mg/ml biotinylated PolyEY (Glu, Tyr 4:1) are combined with 50 nL of serial dilutions of TAE684 (10-500 nM) and 4 ng of InsR enzyme in the presence of the kinase reaction buffer (20 mM Tris譎Cl, pH 7.5/10 mM MgCl2/3 mM MnCl2/1 mM DTT/10 mM NaVO4/0.1 mg/ml of BSA). Assays are incubated for 1 hour at ambient temperature. Reactions are terminated by adding 10 mL of the detection solution containing 50 mM EDTA, 500 mM KF, 0.5 mg/ml of BSA, 5 mg/mL Eu3+ cryptate-labeled anti-phosphotyrosine antibody Mab PT66-K, and 5 mg/mL Streptavidin-XLent. The reaction is incubated for half an hour, and fluorescence signals are read on Analyst GT.

Cell Assay: [1]

Cell lines Luciferase-expressing Karpas-299, SU-DHL-1, and Ba/F3 cells and transformed Ba/F3 stably expressing NPM-ALK, Bcr-Abl, or TEL-kinase fusion constructs.
Concentrations 1 nM-10 μM
Incubation Time 2–3 days
Method Cells are seeded in 384-well plates (2.5×104 cells per well) and incubated with serial dilutions of TAE684 or DMSO for 2–3 days. Luciferase expression is used as a measure of cell proliferation/survival and is evaluated with the Bright-Glo Luciferase Assay System. IC50 values are generated by using XLFit software.

Animal Study: [1]

Animal Models Karpas-299 xenografts are established in 4- to 6-week old female Fox Chase SCIDBeige mice.
Formulation Resuspended in 10% 1-methyl-2-pyrrolidinone/90% polyethylene glycol 300 solution
Dosages 1, 3, and 10 mg/kg
Administration Once daily by oral gavage for 3 weeks

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Galkin AV, et al. Proc Natl Acad Sci U S A, 2007, 104(1), 270-275.

[2] Katayama R, et al. Proc Natl Acad Sci U S A, 2011, 108(18), 7535-7540.

view more

Chemical Information

Download TAE684 (NVP-TAE684) SDF
Molecular Weight (MW) 614.2
Formula

C30H40ClN7O3S

CAS No. 761439-42-3
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 3 mg/mL (4.88 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, pH 4 10 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine

Customer Product Validation (4)


Click to enlarge
Rating
Source Cancer Res 2011 71, 4920-31. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H3122 cells
Concentrations 100 nmol/L
Incubation Time 6 h
Results Figure A shows that the primary adaptors for PI3K activation are IRS1 and IRS2 in H3122 mouse xenografts. Interestingly, treatment with TAE-684 eliminates these interactions, suggesting that ALK signals to PI3K via IRS2 and IRS1. This is consistent with previous reports suggesting that NPM-ALK signals to PI3K via IRS proteins. The finding that IRS proteins were utilized to activate PI3K suggested that these cells might activate PI3K in response to IGF-I. Indeed, treatment of H3122 cells with IGF-I, but not EGF or HGF, rescued PI3K-AKT signaling with TAE-684 treatment (Fig. B).

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Western blot
Cell Lines H-1299 cells
Concentrations 0.03-1uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho-Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Xenograft
Cell Lines mice
Concentrations
Incubation Time 4 weeks
Results Consistently, TAE684 treatment repressed H694R- and E1384K-induced tumor growth compared with DMSO control.

Click to enlarge
Rating
Source Neoplasia 2011 13, 704-15. TAE684 (NVP-TAE684) purchased from Selleck
Method Cell Proliferation Assay
Cell Lines H-1299 cells
Concentrations 0-3 uM
Incubation Time
Results Treatment efficiently inhibited the cell proliferation and phospho- Y1604 ALK expression of H694R or E1384K mutant ALK, but also to a degree higher than that of wild-type ALK.

Product Use Citation (17)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related ALK Products

  • PF-06463922

    PF-06463922 is a potent, dual ALK/ROS1 inhibitor with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively. Phase 1.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • GSK1838705A

    GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.

    Features:A small-molecule kinase inhibitor of IGF-1R and the insulin receptor.

  • Alectinib (CH5424802)

    Alectinib (CH5424802) is a potent ALK inhibitor with IC50 of 1.9 nM in cell-free assays, sensitive to L1196M mutation and higher selectivity for ALK than PF-02341066, NVP-TAE684 and PHA-E429.

  • AP26113

    AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.

    Features:At least 10-fold more potent and selective in ALK inhibition relative to crizotinib.

  • ASP3026

    ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.

  • AZD3463

    AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.

  • Ceritinib (LDK378)

    Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.

    Features:Does not cross react with c-Met, and has an improved in vivo glucose homeostasis profile relative to TAE684. May be active in Crizotinib-relapsed tumors.

  • Gefitinib (ZD1839)

    Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

    Features:A potent EGFR tyrosine kinase inhibitor.

Recently Viewed Items

Tags: buy TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) supplier | purchase TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) cost | TAE684 (NVP-TAE684) manufacturer | order TAE684 (NVP-TAE684) | TAE684 (NVP-TAE684) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us